COMORBIDITATEA COVID-19 - BPOC: PARTICULARITĂȚI ȘI EVOLUȚIE
DOI:
https://doi.org/10.52692/1857-0011.2024.2-79.46Cuvinte cheie:
COVID-19, BPOC, comorbiditate, SARS-CoV-2Rezumat
Potrivit studiilor BPOC în rândul persoanelor infectate cu SARS-CoV2 nu este o patologie concomitentă comună. Frecvența de depistare a BPOC printre bolile concomitente la pacienții cu COVID-19 este detectată mai rar decât în populație generală. Cu toate acestea, BPOC agravează evoluția infecției cu coronavirus, crescînd riscul de rezultate nefaste ale bolii și a riscului de deces. Infecția cu coronavirus la pacienții cu BPOC evoluează mai sever în comparație cu alte boli concomitente și duce mai des la spitalizare în comparație cu alte boli concomitente. BPOC, fiind un factor de risc pentru COVID-19 sever, crește probabilitatea spitalizărilor repetate, transferurilor în secție de terapie intensivă și sporirea numărului deceselor.
Referințe
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. https://goldcopd.org/2024-gold-report/
WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. https://data.who.int/
Alqahtani, J.S., Oyelade, T., Aldhahir, A.M. et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One. 2020; 15 (5):
Zhang, X.Y., Huang, H.J., Zhuang, D.L., et al. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. Infect Dis Poverty. 2020. 9(1). p.99.
Marcello, R.K., Dolle, J., Grami, S. et al. Characteristics and outcomes of COVID-19 patients in New York City’s Public Hospital System. PLoS One. 2020 Dec 17;15(12):e0243027.
Huang, Y., Tan, C., Wu, J., et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir. Res. 2020. 21(1). p. 163.
Beyerstedt, S., Casaro, E.B., Rangel, É.B. COVID-19: Angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARSCoV-2 infection. Eur. J. Clin. Microbiol. Infect. Dis. 2021;40(5):905-919.
Saheb Sharif-Askari, N., Saheb, Sh. F., Alabed, M. et al. Airways expression of SARS-CoV-2 receptor, ACE- 2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD. Version 2. Mol. Ther. Methods Clin. Dev. 2020; 18: 1-6.
Zhou, P., Yang, X.L., Wang, X.G., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270-273.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 16:181(2): 271-280.
Huang, C., Wang, Y., Li, X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506.
Li, G., Fan, Y., Lai, Y., et al. Coronavirus infections and immune responses. Journal of medical virology. 2020; 92(4):424-432. https://doi.org/10.1002/jmv.25685.
Leask, A. COVID-19: is fibrosis the killer? Journal of Cell Communication and Signaling. 2020;14(2):255.
Wang, B., Li, R., Lu, Z., et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020; 12 (7): 6049-6057.
Смирнова, М.И., Антипушина, Д.Н., Курехян, А.С. Хроническая обструктивная болезнь легких и COVID-19: данные к лету 2020 года, подходы к оказанию медицинской помощи и профилактике.Профилактическая медицина. 2020; 23(8):37-44.
Федеральные клинические рекомендации МЗ РФ “Хроническая обструктивная болезнь легких”, 2018. https://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf
Павленко, В.И., Кулик, Е.Г., Нарышкина, С.В. Хроническая обструктивная болезнь легких как коморбидное состояние при COVID-19. Амурский медицинский журнал, 2021, nr. 1, pp. 11-17.
Yin, T, Li, Y, Ying, Y, et al. Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors. BMC Infect Dis. 2021 Feb 22;21(1):200. doi: 10.1186/s12879- 021-05915-0.
Global Initiative for Chronic Obstructive Lung Disease. GOLD COVID-19 Guidance. Available at: GOLD COVID-19 Guidance Global Initiative for Chronic Obstructive Lung Disease GOLD (goldcopd.org).
Fang, X., Li, S., Yu, H., et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging (Albany NY). 2020. 12(13). P.12493-12503.
Yang, X., Yu, Y., Xu, J., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 8(5). P. 475-481. doi: 10.1016/S2213- 2600(20)30079-5.
Lupia, T., Scabini, S., Mornese, P.S. et al. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. J. Glob. Antimicrob. Resist. 2020; 21: 22-27.
Goyal, P., Choi, J.J., Pinheiro, L.C. et al. Clinical characteristics of COVID-19 in New York city: Multicenter study. N. Engl. J. Med. 2020; 382 (24): 2372-2374.
Argenziano, M.G., Bruce, S.L., Slater, C.L. et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ, 2020, vol. 369: m1996.
Svist, P.G., Torchinsky, N.V., Briкo, N.I., et al. Prevalence of bronchial asthma and COPD in comorbidity with COVID-19. Epidemiology and Vaccinal Prevention. 2024; 23(1):66-76 (In Russ.).
Lippi, G., Henry, B.M. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir. Med. 2020. 167. P.105941.
Shchikota, A.M., Pogonchenkova, I.V., Turova, E.A., et al. Chronic obstructive pulmonary disease and COVID-19: topical issues. Pulmonologiya. 2020; 30 (5): 599-608 (in Russian).
Zhao, Q., Meng, M., Kumar, R. et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J. Med. Virol. 2020; 92 (10):1915-1921.
Higham, A., Singh, D. Increased ACE2 expression in the bronchial epithelium of COPD patients who are overweight. Obesity (Silver Spring). 2020; 28 (9): 1586-1589.
Feng, Y., Ling, Y., Bai, T., et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020 Jun 1; 201(11):1380-1388.
Guan, W.J., Ni, Z. Y., Hu, Y., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med., 2020, Vol. 382, № 18. Р. 1708-1720.
Gerayeli, F.V., Milne, S., Cheung, C., et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. E Clinical Medicine. 2021; 33:100789.
Wu, F., Zhou, Y., Wang, Z., et al. Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: A multicenter, retrospective, observational study. J. Thorac. Dis. 2020;12(5):1811-1823.
Somani, S., Richter, F., Fuster, V., et al. Characterization of patients who return to hospital following discharge from hospitalization for COVID-19. medRxiv. 2020.
Docherty, A.B., Harrison, E.M., Green, C.A. et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020; 369: m1985.
Sheikh, D., Tripathi, N., Chandler, T.R., et al. Clinical outcomes in patients with COPD hospitalized with SARS-CoV-2 versus non-SARS-CoV-2 community- acquired pneumonia. Respir. Med. 2022 an; 191: 106714.
Zaryanova, E.A., Osipova, G.L., Osipova, V.V. Chronic obstructive pulmonary disease and COVID-19. Pulmonologiya. 2022; 32 (5): 755-762 (in Russian).
Mehra, M.R., Desai, S.S., Kuy, S., et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N. Engl. J. Med., 2020; 382(25):e102.
Krayushkin, S.I., Ivakhnenko, I.V., Sushchuk, E.A., et al. Management of patients with chronic obstructive pulmonary disease in COVID 19 pandemic. Medical alphabet. 2020; (19): 77-80.
Samoylov, K.V., Bukreeva, E.B., Boyarko, V.V., et al. Features of COVID-19 in patients with chronic obstructive pulmonary disease, bronchial asthma, and cardiovascular comorbidity. The Siberian Journal of Clinical and Exp. Med. 2022; 37(4):63-69.
Cai, H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir. Med. 2020; 8 (4): e20. DOI: 10.1016/S2213-2600(20)30117-X.
Zhang, H., Tang, K., Fang, R., et al. What dermatologists could do to cope with the novel coronavirus (SARS-CoV-2): a dermatologist’s perspective from China. J. Eur. Acad. Dermatol. Venereol. 2020 May;34(5):e211-e212.
Condrațchi, D. Optimizarea expertizei medico-sociale în bronhopneumopatia obstructivă cronică. Rezumatul tezei de doctor în științe medicale. Chișinău, 2024. 31 p.
Moscovciuc, A., Simionica, I., Scaleţchi, V., Şincarenco, I. Bronhopneumopatia obstructivă cronica: interconexiunea genelor candidate ACE cu manifestări clinice de boală (sinteza de literatură). Bulletin of the Academy of Sciences of Moldova. Medical Sciences, 63(3), 271-275.
Emami, A., Javanmardi, F., Pirbonyeh, N., et al. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad Emerg Med. 2020 Mar 24;8(1):e35.
Wu, Z., McGoogan, J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323 (13): 1239-1242.
Silva, A.B., Siqueira, S., et al. Long-COVID and Post- COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. Viruses. 2021 Apr 18;13(4):700.
World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_cond. (6 October 2021).
Descărcări
Publicat
Număr
Secțiune
##category.category##
Licență
Copyright (c) 2025 Buletinul Academiei de Științe a Moldovei. Științe medicale
Această lucrare este licențiată în temeiul Creative Commons Attribution 4.0 International License.
